Atara Biotherapeutics (ATRA) Revenue (2022 - 2026)

Atara Biotherapeutics has reported Revenue for 5 years, with the latest figure at $516000.0 in Q1 2026.

• For the quarter ending Q1 2026, Revenue fell 99.47% year-over-year to $516000.0; the trailing twelve-month figure through Mar 2026 stood at $23.1 million (down 88.41% YoY), and the FY2025 full-year result was $120.8 million, down 6.33% from the prior year.
• Revenue for Q1 2026 stood at $516000.0, down from $1.6 million in the prior quarter.
• The five-year high for Revenue was $98.1 million in Q1 2025, with the low at $221000.0 in Q4 2022.
• Historically, Revenue has averaged $19.9 million across 5 years, with a median of $6.1 million in 2022.
• Annual changes were most pronounced in 2024 — Revenue surged 3511.6% — and 2026, when it sank 99.47%.
• Atara Biotherapeutics' Revenue stood at $221000.0 in 2022, then surged by 2106.33% to $4.9 million in 2023, then surged by 571.72% to $32.8 million in 2024, then tumbled by 95.13% to $1.6 million in 2025, then sank by 67.65% to $516000.0 in 2026.
• The last three Revenue figures came in at $516000.0 (Q1 2026), $1.6 million (Q4 2025), and $3.5 million (Q3 2025), per Business Quant data.